Israeli Pharmaceutical Companies See Decline in Shares

1 Mins read

Shares of Israeli pharmaceutical companies have experienced a drop in premarket trading on Monday in the aftermath of the recent attack by Hamas on Israel.

Teva Pharmaceutical Industries Ltd.

Israeli pharmaceutical giant, Teva Pharmaceutical Industries Ltd. (TEVA), has seen a 4% decrease in its shares.

Taro Pharmaceutical Industries Ltd.

Shares of Taro Pharmaceutical Industries Ltd. (TARO) have also been impacted, with a decrease of 2.6%.

Kamada Ltd.

Biopharmaceutical company, Kamada Ltd. (KMDA), has observed a significant decline of 6.1% in its stock value.

Protalix BioTheraputics Inc.

The stock of Protalix BioTheraputics Inc. (PLX) has experienced a decrease of 5.5%.

Protalix released a statement expressing their condolences and solidarity with the victims of the ongoing attacks in Israel. However, they reassured their employees, partners, and stockholders that their operations remain unaffected by the situation and that there will be no disruption to the supply of their products.

Compugen Ltd.

Drug discovery and development company, Compugen Ltd. (CGEN), has witnessed a 6.6% decrease in shares on Monday.

Gamida Cell Ltd.

Gamida Cell Ltd. (GMDA) has experienced a decline of 7.4% in premarket trades on Monday.

These recent developments highlight the impact of the attack on Israeli society, including its pharmaceutical industry.

Related posts

Government Matching Contribution for Retirement Savings

2 Mins read
According to researchers, nearly 22 million Americans are set to benefit from a new government matching contribution initiative aimed at enhancing retirement…

Oil Market Update

1 Mins read
Oil Market Update On Tuesday, crude oil futures prices were lower, while refined product contracts were experiencing a second consecutive day of…

Carrier Global Sells Industrial Fire Business

1 Mins read
Carrier Global Sells Industrial Fire Business for $1.425 Billion Carrier Global has announced the sale of its industrial fire business to private-equity…

Leave a Reply

Your email address will not be published. Required fields are marked *